Authorised Indian Distributor
Saxsons Group
New Delhi, India · Since 1997
No-carrier-added Lutetium-177 (produced by SHINE Medical, supplied across India by Saxsons) paired with DOTATATE peptide for peptide receptor radionuclide therapy in somatostatin-receptor-positive neuroendocrine tumours. The NETTER-1 / NETTER-2 standard-of-care protocol — n.c.a. starting material, ≥99.9 % radionuclidic purity, AERB-importable, delivered cold-chain across India.
| Radionuclide | Lutetium-177 (Lu-177) |
| Production route | No-carrier-added (n.c.a.) reactor irradiation |
| Half-life | 6.647 days |
| Decay emissions | β⁻ (max 498 keV); γ 113 keV, 208 keV |
| Specific activity | n.c.a. — highest batch-specific (TBq/mg) |
| Chemical form | Lutetium(III) chloride in 0.04 M HCl |
| Radionuclidic purity | ≥ 99.9% Lu-177 (Ph. Eur. compliant) |
| Lu-177m contamination | < 0.001% (minimises long-term radiation burden) |
| Clinical indication | Somatostatin receptor-positive gastroenteropancreatic NETs (SSTR2+) |
| Labelling target | DOTATATE (177Lu-DOTATATE / Lutathera) |
| Standard therapy dose | 7.4 GBq per cycle; 4 cycles at 8-week intervals |
| AERB status | Import licence required; full documentation support available |
PRRT — transforming neuroendocrine tumour outcomes
Standard of care for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Lu-177-DOTATATE delivers β-radiation directly to SSTR2-expressing tumour cells.
Expanding indication for SSTR2-positive pulmonary carcinoids and atypical carcinoids progressing after somatostatin analogue therapy.
Post-therapy Ga-68 DOTATATE PET/CT for response assessment. The same SSTR2 target enables true theranostic pairing — one imaging agent, one therapy agent.
The 208 keV gamma from Lu-177 enables SPECT/CT dosimetry after each cycle. Personalised cycle dose adjustment based on tumour and kidney dosimetry.
Re-treatment protocols for patients relapsing after initial PRRT. n.c.a. purity ensures consistent labelling efficiency in second-line therapy.
Investigational combination with chemotherapy (CAPTEM) and targeted agents (mTOR inhibitors) in progressive NETs. n.c.a. Lu-177 is the regulatory-compliant standard.
n.c.a. Lu-177 has no stable lutetium carrier, giving the highest specific activity and lowest cold-metal DOTATATE competition. This maximises tumour uptake and minimises pharmacological peptide load — critical for repeat PRRT cycles where cumulative renal dose matters.
Lu-177m (metastable) has a 160-day half-life and contributes disproportionate long-term kidney dose. Our n.c.a. production consistently achieves Lu-177m < 0.001% — the lowest contamination standard available in clinical supply.
PRRT requires 4 cycles at 8-week intervals. Saxsons maintains a regular India supply schedule — your department receives Lu-177 on therapy day, calibrated to the planned activity at the time of labelling.
SHINE product page for the upstream Lu-177 n.c.a. starting material. Contact Saxsons for AERB import documentation, cold-chain scheduling and DOTATATE peptide kit pairing.
Lu-177 + DOTATATE
Each card opens a focused post for a specific specialty — peer-reviewed evidence and clinical workflow, written for the persona you select.
For Nuclear-Medicine Physician
First-line ¹⁷⁷Lu-DOTATATE in grade 2/3 GEP-NETs — 22.8 vs 8.5 month PFS, 43 % vs 9.3 % ORR. What changes in the Indian PRRT selection SOP, six patient-selection criteria for first-line use.
Read this Nuclear-Medicine PhysicianAcross four cycles, three Lu-177 specs decide SSTR2 receptor saturation, kidney dose tail and labelling yield. Why ≥ 3,000 GBq/mg specific activity, ≥ 99.9 % RNP and ≥ 99 % RCP are what NETTER chemistry actually requires.
Read thisContact Saxsons Group for Lu-177 + DOTATATE supply, AERB import documentation and dosimetry consultation for your neuroendocrine tumour therapy programme.